Patient characteristics
| Variable . | UPN-01 . | UPN-02 . | UPN-03 . | UPN-04 . |
|---|---|---|---|---|
| Age, y | 65 | 80 | 62 | 28 |
| Sex | Male | Male | Male | Male |
| Diagnosis | MCL | MCL | MCL | FL |
| Stage | IV | IV | IV | IV |
| Therapies before study entry | R, fenretinide, R-CHOP, ASCT | R-CHOP, fludarabine, colectomy, R, bortezomib, fenretinide | CHOP, ASCT | R-CHOP, R maintenance |
| Cytoreductive therapy during T-cell expansion | NA | Bendamustine, GCD, | None | None |
| 36 Gy RT to neck | ||||
| Last systemic therapy before T-cell infusions | ASCT | GCD | ASCT | R |
| Clinical response to last systemic therapy | PR | SD | CR | SD |
| Duration of response | 20 mo | Received RT 2 mo later | 12 y | 10 mo |
| Time between last treatment and first T-cell infusion | NA | 4 mo since GCD; 4 wks since RT | > 13 y | > 10 mo |
| Last anti-CD20 Ab therapy before T-cell infusions | NA | > 3 y | > 13 y | > 10 mo |
| Baseline B cell count (cells/μL) | NA | 1 | 277 | 40 |
| Variable . | UPN-01 . | UPN-02 . | UPN-03 . | UPN-04 . |
|---|---|---|---|---|
| Age, y | 65 | 80 | 62 | 28 |
| Sex | Male | Male | Male | Male |
| Diagnosis | MCL | MCL | MCL | FL |
| Stage | IV | IV | IV | IV |
| Therapies before study entry | R, fenretinide, R-CHOP, ASCT | R-CHOP, fludarabine, colectomy, R, bortezomib, fenretinide | CHOP, ASCT | R-CHOP, R maintenance |
| Cytoreductive therapy during T-cell expansion | NA | Bendamustine, GCD, | None | None |
| 36 Gy RT to neck | ||||
| Last systemic therapy before T-cell infusions | ASCT | GCD | ASCT | R |
| Clinical response to last systemic therapy | PR | SD | CR | SD |
| Duration of response | 20 mo | Received RT 2 mo later | 12 y | 10 mo |
| Time between last treatment and first T-cell infusion | NA | 4 mo since GCD; 4 wks since RT | > 13 y | > 10 mo |
| Last anti-CD20 Ab therapy before T-cell infusions | NA | > 3 y | > 13 y | > 10 mo |
| Baseline B cell count (cells/μL) | NA | 1 | 277 | 40 |
FL indicates follicular lymphoma; R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; ASCT, high-dose therapy followed by autologous stem cell transplantation; GCD, gemcitabine, carboplatin, and dexamethasone; RT, radiotherapy; PR, partial response; SD, stable disease; CR, complete response; and NA, not applicable.